A | THE GOOD NEWS FOR THE BIOPHARMA INDUSTRY IS THAT WE HAVE AN OPPORTUNITY to improve the perception of our industry. The rapid worldwide response to the pandemic was impressive (basic science, therapeutics, diagnostics, devices, and vaccines). It is my hope the industry can continue to be viewed as leaders and focused on solutions to unmet medical challenges. The second insight is the willingness of the capital markets to invest in innovation and public health. I am not just looking at the stock market but also the amount of capital in the aggregate flowing into our sector. The last insight is the willingness of biopharma to adopt a more flexible selling model to our end customer. For the first time, models are emerging that are less rigid and can be adapted to local needs.
AL ALTOMARI is chairman and CEO of Agile Therapeutics and a member of the company’s board of directors.